Molecular studies have further implicated STAT1, STAT2, and STAT3 activation in the pathogenesis of rosacea [10-12]. By inhibiting this pathway, JAK inhibitors attenuate this inflammatory cascade. The gene discussed is STAT3; the disease is rosacea.